IBDEI1HL ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,23770,1,4,0)
 ;;=4^I63.81
 ;;^UTILITY(U,$J,358.3,23770,2)
 ;;=^5157372
 ;;^UTILITY(U,$J,358.3,23771,0)
 ;;=Z91.5^^105^1187^1
 ;;^UTILITY(U,$J,358.3,23771,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23771,1,3,0)
 ;;=3^Personal Hx of One or More Suicide Attempts
 ;;^UTILITY(U,$J,358.3,23771,1,4,0)
 ;;=4^Z91.5
 ;;^UTILITY(U,$J,358.3,23771,2)
 ;;=^5063624
 ;;^UTILITY(U,$J,358.3,23772,0)
 ;;=R45.851^^105^1187^2
 ;;^UTILITY(U,$J,358.3,23772,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23772,1,3,0)
 ;;=3^Suicidal Ideations
 ;;^UTILITY(U,$J,358.3,23772,1,4,0)
 ;;=4^R45.851
 ;;^UTILITY(U,$J,358.3,23772,2)
 ;;=^5019474
 ;;^UTILITY(U,$J,358.3,23773,0)
 ;;=T14.91XA^^105^1187^3
 ;;^UTILITY(U,$J,358.3,23773,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23773,1,3,0)
 ;;=3^Suicide Attempt,Initial Encntr
 ;;^UTILITY(U,$J,358.3,23773,1,4,0)
 ;;=4^T14.91XA
 ;;^UTILITY(U,$J,358.3,23773,2)
 ;;=^5151779
 ;;^UTILITY(U,$J,358.3,23774,0)
 ;;=T14.91XD^^105^1187^4
 ;;^UTILITY(U,$J,358.3,23774,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23774,1,3,0)
 ;;=3^Suicide Attempt,Subsequent Encntr
 ;;^UTILITY(U,$J,358.3,23774,1,4,0)
 ;;=4^T14.91XD
 ;;^UTILITY(U,$J,358.3,23774,2)
 ;;=^5151780
 ;;^UTILITY(U,$J,358.3,23775,0)
 ;;=T14.91XS^^105^1187^5
 ;;^UTILITY(U,$J,358.3,23775,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23775,1,3,0)
 ;;=3^Suicide Attempt,Sequela
 ;;^UTILITY(U,$J,358.3,23775,1,4,0)
 ;;=4^T14.91XS
 ;;^UTILITY(U,$J,358.3,23775,2)
 ;;=^5151781
 ;;^UTILITY(U,$J,358.3,23776,0)
 ;;=Z51.81^^105^1188^3
 ;;^UTILITY(U,$J,358.3,23776,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23776,1,3,0)
 ;;=3^Therapeutic Drug Level Monitoring
 ;;^UTILITY(U,$J,358.3,23776,1,4,0)
 ;;=4^Z51.81
 ;;^UTILITY(U,$J,358.3,23776,2)
 ;;=^5063064
 ;;^UTILITY(U,$J,358.3,23777,0)
 ;;=Z02.89^^105^1188^1
 ;;^UTILITY(U,$J,358.3,23777,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23777,1,3,0)
 ;;=3^Administrative Exam,Other
 ;;^UTILITY(U,$J,358.3,23777,1,4,0)
 ;;=4^Z02.89
 ;;^UTILITY(U,$J,358.3,23777,2)
 ;;=^5062645
 ;;^UTILITY(U,$J,358.3,23778,0)
 ;;=Z79.01^^105^1188^2
 ;;^UTILITY(U,$J,358.3,23778,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23778,1,3,0)
 ;;=3^L/T Use of Anticoagulants
 ;;^UTILITY(U,$J,358.3,23778,1,4,0)
 ;;=4^Z79.01
 ;;^UTILITY(U,$J,358.3,23778,2)
 ;;=^5063330
 ;;^UTILITY(U,$J,358.3,23779,0)
 ;;=E11.21^^105^1189^33
 ;;^UTILITY(U,$J,358.3,23779,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23779,1,3,0)
 ;;=3^Type 2 DM w/ Nephropathy
 ;;^UTILITY(U,$J,358.3,23779,1,4,0)
 ;;=4^E11.21
 ;;^UTILITY(U,$J,358.3,23779,2)
 ;;=^5002629
 ;;^UTILITY(U,$J,358.3,23780,0)
 ;;=E11.22^^105^1189^31
 ;;^UTILITY(U,$J,358.3,23780,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23780,1,3,0)
 ;;=3^Type 2 DM w/ CKD
 ;;^UTILITY(U,$J,358.3,23780,1,4,0)
 ;;=4^E11.22
 ;;^UTILITY(U,$J,358.3,23780,2)
 ;;=^5002630
 ;;^UTILITY(U,$J,358.3,23781,0)
 ;;=E11.40^^105^1189^34
 ;;^UTILITY(U,$J,358.3,23781,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23781,1,3,0)
 ;;=3^Type 2 DM w/ Neuropathy,Unspec
 ;;^UTILITY(U,$J,358.3,23781,1,4,0)
 ;;=4^E11.40
 ;;^UTILITY(U,$J,358.3,23781,2)
 ;;=^5002644
 ;;^UTILITY(U,$J,358.3,23782,0)
 ;;=E11.65^^105^1189^32
 ;;^UTILITY(U,$J,358.3,23782,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23782,1,3,0)
 ;;=3^Type 2 DM w/ Hyperglycemia
 ;;^UTILITY(U,$J,358.3,23782,1,4,0)
 ;;=4^E11.65
 ;;^UTILITY(U,$J,358.3,23782,2)
 ;;=^5002663
